Collegium Pharmaceutical, Inc.
COLLNASDAQHealthcare● Active
$33.27
$-0.11(-0.33%)
Market Cap$1.1B
P/E Ratio—
52W High$50.787
52W Low$29.08
Collegium Pharmaceutical, Inc. (COLL) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · COLL · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | $0.06B | $0.07B | $0.05B | ($0.03B) | $0.07B |
| Depreciation & Amort. | $0.22B | $0.17B | $0.15B | $0.14B | $0.07B |
| Stock-Based Comp. | $0.04B | $0.03B | $0.03B | $0.02B | $0.02B |
| Change in Working Capital | $0.00B | ($0.05B) | $0.02B | ($0.01B) | $0.01B |
| Net Cash from Operations | $0.33B | $0.20B | $0.27B | $0.12B | $0.10B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($0.13B) | ($0.11B) | ($0.09B) | $0.00B | $0.00B |
| Sales of Investments | $0.07B | $0.09B | $0.02B | $0.00B | $0.00B |
| Net Cash from Investing | ($0.06B) | ($0.29B) | ($0.07B) | ($0.57B) | ($0.00B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.03B) | ($0.06B) | ($0.07B) | ($0.01B) | ($0.05B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | ($0.07B) | $0.01B | ($0.07B) | $0.44B | ($0.05B) |
| Net Cash from Financing | ($0.11B) | ($0.06B) | ($0.14B) | $0.44B | ($0.09B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.33B | $0.20B | $0.27B | $0.12B | $0.10B |
| FCF Margin %(computed) | 41.97% | 32.20% | 48.40% | 26.43% | 36.70% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · B
Explore more Collegium Pharmaceutical, Inc. data
About Collegium Pharmaceutical, Inc. (COLL) Cash Flow Statement
Collegium Pharmaceutical, Inc. generated operating cash flow of $0.33B and free cash flow of $0.33B for 2025 — a FCF margin of 41.97%. Capital expenditure was ($0.00B).
Frequently asked questions
COLL · 4 questionsCollegium Pharmaceutical, Inc. generated free cash flow of $0.33B for 2025, up 61.1% year-over-year.
COLL free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10